Ebola Death Rate: Case Fatality Rates Across All Outbreaks Explained
Why does Ebola's death rate range from 25% to 90%? This article explains case fatality rates (CFR) across all 31+ Ebola outbreaks, the factors that drive variation, and how modern treatment is changing outcomes.
The Question Everyone Asks First
When people hear about Ebola, one of the first questions is: “What’s the death rate?” The honest answer is: it depends — and it varies enormously. Ebola’s case fatality rate (CFR) ranges from 0% (Reston ebolavirus in humans) to 90% (1976 Yambuku, Republic of Congo 2002) depending on the species, the outbreak setting, and the quality of medical care available.
Understanding why CFR varies is crucial for calibrating the public health threat — and for understanding why the 2026 DRC outbreak’s current ~66% CFR is not surprising, but not inevitable either.
What Is Case Fatality Rate?
Case fatality rate (CFR) = (Number of deaths / Number of confirmed cases) × 100%
CFR is a measure of how deadly an infection is among people who are confirmed to have it, not among all exposed people. It’s distinct from infection fatality rate (IFR), which includes undetected mild or subclinical infections.
For Ebola, there is no reliable data on what proportion of exposures result in confirmed cases — it is possible that some mild or subclinical Ebola infections occur and go undetected. Seroprevalence studies in forest communities suggest some exposure may go undiagnosed, potentially meaning the true IFR is lower than CFR suggests.
Variation by Species
The species of ebolavirus is the single strongest predictor of CFR:
| Species | Typical CFR Range | Note |
|---|---|---|
| Zaire ebolavirus | 60–90% (untreated) | Most dangerous species |
| Sudan ebolavirus | 41–65% | Somewhat less lethal |
| Bundibugyo ebolavirus | 25–47% | Lowest CFR among pathogenic species |
| Tai Forest ebolavirus | 0% (1 case, survived) | Too few cases to characterise |
| Reston ebolavirus | 0% | Does not cause human disease |
The difference between species likely relates to differences in their glycoproteins’ interaction with human cell receptors, the efficiency of immune evasion mechanisms, and the degree to which they dysregulate the host immune response.
Historical CFRs: Outbreak by Outbreak
| Year | Location | Species | Cases | Deaths | CFR |
|---|---|---|---|---|---|
| 1976 | Yambuku, DRC | Zaire | 318 | 280 | 88% |
| 1976 | Nzara, Sudan | Sudan | 284 | 151 | 53% |
| 1979 | Nzara, Sudan | Sudan | 34 | 22 | 65% |
| 1995 | Kikwit, DRC | Zaire | 315 | 254 | 81% |
| 2000 | Gulu, Uganda | Sudan | 425 | 224 | 53% |
| 2002 | Mbomo, Congo | Zaire | 143 | 128 | 90% |
| 2007 | Kasai, DRC | Zaire | 264 | 187 | 71% |
| 2007 | Bundibugyo, Uganda | Bundibugyo | 149 | 37 | 25% |
| 2013-16 | West Africa | Zaire | 28,616 | 11,310 | 40% |
| 2018-20 | DRC Kivu | Zaire | 3,481 | 2,299 | 66% |
| 2022 | Uganda | Sudan | 164 | 55 | 34% |
| 2026 | DRC North Kivu | Zaire | 47+ | 31+ | ~66% |
Why Did West Africa’s CFR Drop to 40%?
The 2014–2016 West Africa epidemic had a CFR of approximately 40% — dramatically lower than historical Zaire ebolavirus outbreaks that typically showed 70–90% CFR. Why?
Several factors contributed:
1. Better supportive care at scale MSF, WHO, and other organisations established large Ebola Treatment Units (ETUs) providing IV fluid resuscitation, electrolyte replacement, and basic medical monitoring. Even without specific antivirals, aggressive supportive care significantly reduced mortality.
2. Earlier presentation and treatment As the epidemic progressed and community awareness grew, some patients sought care earlier in the disease course — when viral loads were lower and survival prospects better.
3. Possible strain differences The West Africa epidemic was caused by a specific variant (Makona variant) that some researchers suggest may have had slightly different virulence characteristics. The A82V mutation was identified in the GP gene, and while its effect on virulence is debated, it may have altered disease progression.
4. Selection bias in later epidemic phases As response capacity improved, more mild cases were detected and confirmed — mathematically lowering the CFR because the denominator grew faster than the numerator.
Why Was the 2018–2020 DRC Kivu CFR 66%?
Despite the DRC Kivu outbreak having access to experimental treatments (ZMapp, later Inmazeb and Ebanga through the PALM trial), the CFR was 66% — higher than West Africa’s 40%. Key reasons:
1. Access and security Many patients in Kivu could not reach treatment centres due to active armed conflict. Late-presenting patients have much higher mortality.
2. Community resistance Some patients were hidden by families or fled treatment centres due to distrust, presenting only when critically ill.
3. Different baseline care environment Unlike West Africa where MSF built large structured ETUs, the conflict environment in Kivu limited care capacity.
4. The PALM trial population The 499 patients enrolled in the PALM trial were already hospitalised patients — likely sicker on average. The 33–35% trial mortality (for the best treatment arms) represents care for already-hospitalised patients with confirmed disease.
How Treatment Is Changing CFR
The approval of Inmazeb and Ebanga represents a genuine breakthrough. The PALM trial data:
- Inmazeb: 28-day mortality 33.5% vs 49.7% for ZMapp
- Ebanga: 28-day mortality 35.1% vs 49.7% for ZMapp
- In patients with low viral loads at presentation: ~9% mortality with best treatments
If patients can be reached early — before viral loads peak — modern treatment can reduce Ebola CFR to levels approaching 10%. This is the goal of rapid detection, contact tracing, and early Ebola Treatment Unit presentation that health authorities are pursuing in the 2026 DRC outbreak.
The CFR Gap: Treatment Access vs. Availability
The fundamental challenge in 2026 is not whether effective treatments exist — they do. The challenge is getting patients to treatment early enough, in a conflict-affected region with difficult terrain, community hesitancy, and limited health infrastructure. This is why CFR in field settings (66%) remains far above what clinical trials (33%) suggest is achievable under optimal conditions.
Closing this gap — between laboratory efficacy and real-world effectiveness — is the defining challenge of modern Ebola response.